Below is a list of speakers who will present at the 40th Annual UNC Lineberger Symposium, titled "Molecularly Targeted Cancer Therapies from Bench to Bedside." The Symposium will be held April 11 - 12, 2016 at the Friday Center in Chapel Hill, NC.

Dafna Bar-Sagi
New York University Langone Medical Center

Oncogenic RAS-dependent determinants of tumor fitness

Gideon E. Bollag
Plexxikon Inc.

Optimization of kinase-targeted cancer therapies

Sharon L. Campbell
UNC Lineberger Comprehensive Cancer Center

Ras isoform and mutation specific differences

Christopher M. Counter
Duke University School of Medicine

Codon bias: the silent secret of RAS genes

Channing J. Der
UNC Lineberger Comprehensive Cancer Center

Targeting KRAS in pancreatic cancer: is MYC the key?

Jeffrey A. Engelman 
Massachusetts General Hospital and Harvard Medical School

Evolution of resistance to targeted therapies

Stephen W. Fesik 
Vanderbilt University School of Medicine

Cancer drug discovery using fragment-based methods

Keith T. Flaherty
Massachusetts General Hospital, Harvard Medical School

Attempting to translate lessons from BRAF mutant to RAS mutant cancers

William C. Hahn 
Dana-Farber Cancer Institute

Systemic identification of cancer targets

Tyler Jacks 
Massachusetts Institute of Technology

Engineering the cancer genome

Shiva Malek 
Genentech, Inc

RAF kinases as molecular switches: conserved mechanisms drive oncogenic mutations and deletions

Deborah K. Morrison 
National Cancer Institute

Regulation of RAS to RAF signaling in normal and disease states

Neal Rosen
Memorial Sloan Kettering Cancer Center

Comprehensive functional characterization of mutant BRAF alleles-basic and translational implications

David A. Tuveson 
Cold Spring Harbor Laboratory

Modeling pancreatic cancer

Michael A. White
UT-Southwestern Medical Center

Chemically addressable subtypes of KRAS lung cancer

Kris C. Wood
Duke University School of Medicine

Convergent evolution of resistance to targeted therapies